Navigation Links
Elevated temperature enhances success of viral cancer therapy

A therapeutic approach for battling cancer that is based on infection with a specially designed virus similar to the one that causes the common cold has shown promise in clinical trials. Now, new research suggests that fever might be a useful weapon in the fight as well. The study, published in the July issue of Cancer Cell, demonstrates that tumor cells are even more sensitive to viral therapy after they have been incubated at an elevated temperature. The findings could have a significant impact on the future success of viral strategies for cancer therapy.

ONYX-015 is a mutated adenovirus that undergoes selective replication in tumor cells until the cells become so full of virus that they burst and die. The virus is modified so that it only copies itself in tumor cells and is safe for normal cells. In clinical trials, ONYX-015 was a successful therapy for many cancer patients, but the success varied considerably for reasons that were not well understood. Dr. Clodagh C. O'Shea and colleagues from the Cancer Research Institute at the University of California, San Francisco examined why ONYX-015 did not undergo replication in some cancer cells and if it might be possible to sensitize tumor cells to ONYX-015 therapy.

The researchers demonstrated that resistant tumor cells fail to complete an RNA export function that is necessary for ONYX-015 replication. Interestingly, when a cellular heat shock response was induced in the resistant tumor cells, either pharmacologically or by incubating the cells at an elevated temperature similar to that experienced by humans when they have a fever, the RNA export function was restored. Therefore, induction of the heat shock response could rescue ONYX-015 replication in resistant tumor cells.

According to Dr. O'Shea, "Our data suggest that a clinical strategy that does not advocate the use of pharmacological agents to suppress fever would favor the tumor-selective replication of ONYX-015. This study indicates th at induction of a heat shock response by pharmacological agents (that could potentially be administered systemically) or local hyperthermia, could greatly augment and broaden ONYX-015's clinical utility as a cancer therapy."

Clodagh C. O'Shea, Conrado Soria, Bridget Bagus, and Frank McCormick: "Heat shock phenocopies E1B-55K late functions and selectively sensitizes refractory tumor cells to ONYX-015 oncolytic viral therapy" Publishing in Cancer Cell, Vol. 8, July 2005, pages 61-74 . DOI 10.1016/j.ccr.2005.06.009 www.cancercell.org


'"/>

Source:Cell Press


Related biology news :

1. Climate model links higher temperatures to prehistoric extinction
2. Taking evolutions temperature: Researchers pinpoint the energy it takes to make a species
3. Ocean temperature predicts spread of marine species
4. Rising ocean temperatures, pollution have oysters in hot water
5. Healthy coral reefs hit hard by warmer temperatures
6. Pulsating ultrasound enhances gene therapy for tumors
7. NYU algorithm enhances ability to detect cancer genes
8. Proteasome activator enhances survival of Huntingtons disease neuronal model cells
9. New, automated tool successfully classifies and relates proteins in unprecedented way
10. Biomarkers isolated from saliva successfully predict oral and breast cancer
11. Secret of smallpoxs success may lead to bioterror cure
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/21/2016)... Lithuania , Nov. 21, 2016   ... and object recognition technologies, today announced that the ... smart cards was submitted for the NIST ... successfully passed all the mandatory steps of the ... evaluation is a continuing test of fingerprint templates ...
(Date:11/17/2016)... it has just released a new white paper authored by Zettar that covers the ... transfer storage solutions. Photo - http://photos.prnewswire.com/prnh/20161116/440463 ... ... ... Setting up a high performance computing or HPC system can be a complicated endeavor ...
(Date:11/15/2016)... Research and Markets has announced the addition of the ... offering. ... The global bioinformatics market is ... Billion in 2016, growing at a CAGR of 21.1% during the ... driven by the growing demand for nucleic acid and protein sequencing, ...
Breaking Biology News(10 mins):
(Date:12/2/2016)... ... December 02, 2016 , ... Robots will storm the Prudential Center in ... 2016. The event, which is held on the United Nations International Day of Persons ... back into the workplace. Suitable Technologies is partnering with NTI to showcase how technology ...
(Date:11/30/2016)... , ... November 30, 2016 , ... ... moving magnet Voice Coil Actuator with a flexure design that ensures high alignment ... with cost-effective pricing and is ideally suited where extreme precision is required, such ...
(Date:11/30/2016)... Nov. 30, 2016 Biotest Pharmaceuticals Corporation (BPC), ... to announce the addition of its newest plasma collection ... Nebraska . The 15,200 square foot state-of-the-art facility ... 2016 and brings the total number of BPC,s plasma ... Carlisle , BPC,s Chief Executive Officer said "We are ...
(Date:11/30/2016)... BEIJING , Nov. 30, 2016 Novogene ... services and solutions with cutting edge next-generation sequencing (NGS) ... a USD $75 Million [515 Million RMB] B round ... Capital Management ( Shenzhen ) Co., Ltd. ... Innovation") and Shanghai Sigma Square Investment Center LP ("Sigma ...
Breaking Biology Technology: